NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $878.29 -3.41 (-0.39%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$875.62▼$883.3450-Day Range$775.18▼$881.7052-Week Range$668.00▼$899.86Volume534,334 shsAverage Volume610,387 shsMarket Capitalization$95.69 billionP/E Ratio25.05Dividend YieldN/APrice Target$908.12 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside3.4% Upside$908.12 Price TargetShort InterestHealthy1.17% of Float Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment0.55Based on 25 Articles This WeekInsider TradingSelling Shares$8.01 M Sold Last QuarterProj. Earnings Growth5.65%From $36.26 to $38.31 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector430th out of 950 stocksPharmaceutical Preparations Industry202nd out of 442 stocks 2.3 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 19 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $908.12, Regeneron Pharmaceuticals has a forecasted upside of 3.4% from its current price of $878.29.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.17% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 0.81%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 2.5 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Regeneron Pharmaceuticals this week, compared to 12 articles on an average week.Search InterestOnly 14 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.MarketBeat Follows17 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 467% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,012,021.00 in company stock.Percentage Held by InsidersOnly 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions84.15% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 5.65% in the coming year, from $36.26 to $38.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 25.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 105.36.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 25.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 68.30.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 3.25. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesDecember 8, 2023 | marketbeat.com3 biotech powerhouses poised to thrive amid sector reboundIf the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.December 31, 2023 | ca.finance.yahoo.comREGN Feb 2024 830.000 putDecember 31, 2023 | MarketBeat Internal (Ad)Claim Your $300 MarketBeat Account CreditClick the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)December 31, 2023 | ca.finance.yahoo.comREGN Jan 2024 860.000 putDecember 31, 2023 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Michael S. Brown Sells 2,049 SharesDecember 31, 2023 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) SVP Christopher R. Fenimore Sells 2,448 SharesDecember 29, 2023 | msn.comRegeneron expands battle over Eylea patents in new lawsuit against Samsung BioepisDecember 29, 2023 | gurufocus.comRegeneron Pharmaceuticals Inc (REGN)'s Winning Formula: Financial Metrics and Competitive StrengthsDecember 31, 2023 | MarketBeat Internal (Ad)MarketBeat All Access New Year's Sale - Just $1.00Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.December 28, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Canopy Growth (CGC)December 28, 2023 | msn.comRegeneron Celebrates Legal Win: Court Upholds Eylea Medication PatentDecember 28, 2023 | msn.comRegeneron gains after mixed ruling in patent suit over Eylea vs Viatris (update)December 28, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at StockNews.comDecember 27, 2023 | finance.yahoo.comRegeneron Gains After Eye-Drug Patent Victory Over ViatrisDecember 27, 2023 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) SVP Christopher R. Fenimore Sells 1,680 Shares of StockDecember 25, 2023 | benzinga.comRegeneron Pharmaceuticals Stock (NASDAQ:REGN) Dividends: History, Yield and DatesDecember 25, 2023 | ca.finance.yahoo.comREGN Dec 2023 852.500 putDecember 22, 2023 | benzinga.comUnpacking the Latest Options Trading Trends in Regeneron PharmaceuticalsDecember 22, 2023 | finance.yahoo.comThese 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably WellDecember 21, 2023 | benzinga.com$1000 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth This Much TodayDecember 21, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by StockNews.com to BuyDecember 19, 2023 | ca.finance.yahoo.comREGN Dec 2025 940.000 callDecember 19, 2023 | ca.finance.yahoo.comREGN Jan 2026 800.000 putDecember 18, 2023 | markets.businessinsider.com14 Analysts Assess Regeneron Pharmaceuticals: What You Need To KnowDecember 18, 2023 | finance.yahoo.comRegeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 16, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Regeneron (REGN)December 16, 2023 | finance.yahoo.comInsider Sell Alert: Director Bonnie Bassler Sells Shares of Regeneron Pharmaceuticals IncSee More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees11,851Year Founded1988Price Target and Rating Average Stock Price Target$908.12 High Stock Price Target$1,050.00 Low Stock Price Target$680.00 Potential Upside/Downside+3.4%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage26 Analysts Profitability EPS (Most Recent Fiscal Year)$35.06 Trailing P/E Ratio25.05 Forward P/E Ratio24.22 P/E Growth3.25Net Income$4.34 billion Net Margins30.47% Pretax Margin33.42% Return on Equity18.61% Return on Assets14.49% Debt Debt-to-Equity Ratio0.11 Current Ratio5.18 Quick Ratio4.47 Sales & Book Value Annual Sales$13.10 billion Price / Sales7.31 Cash Flow$44.54 per share Price / Cash Flow19.72 Book Value$207.31 per share Price / Book4.24Miscellaneous Outstanding Shares108,947,000Free Float99,327,000Market Cap$95.69 billion OptionableOptionable Beta0.14 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 70)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $7MDr. George D. Yancopoulos M.D. (Age 63)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $6.59MMr. Robert E. Landry Jr. (Age 59)Executive VP of Finance & CFO Comp: $1.84MDr. Andrew J. Murphy Ph.D. (Age 64)Executive Vice President of Research Comp: $1.62MMr. Daniel P. Van Plew (Age 50)Executive VP and GM of Industrial Operations & Product Supply Comp: $1.95MMs. Marion E. McCourt (Age 63)Executive Vice President of Commercial Comp: $1.5MMs. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Christopher R. Fenimore CPA (Age 52)Senior VP, Head of Accounting & Controller Mr. Gerald UnderwoodSenior Vice President of Technical OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMore ExecutivesKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXAllerganNYSE:AGNAlexion PharmaceuticalsNASDAQ:ALXNAlnylam PharmaceuticalsNASDAQ:ALNYZoetisNYSE:ZTSView All CompetitorsInsiders & InstitutionsChristopher R FenimoreSold 2,448 sharesTotal: $2.10 M ($856.71/share)Michael S BrownSold 2,049 sharesTotal: $1.84 M ($898.00/share)Christopher R FenimoreSold 1,680 sharesTotal: $1.42 M ($844.01/share)Vanguard Group Inc.Sold 58,533 shares on 12/18/2023Ownership: 8.076%Gladius Capital Management LPSold 30,000 shares on 12/18/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions REGN Stock Analysis - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price target for 2024? 26 brokers have issued 1-year price targets for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $680.00 to $1,050.00. On average, they expect the company's stock price to reach $908.12 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2023? Regeneron Pharmaceuticals' stock was trading at $721.49 at the beginning of the year. Since then, REGN stock has increased by 21.7% and is now trading at $878.29. View the best growth stocks for 2023 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 2nd 2024. View our REGN earnings forecast. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported $10.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.39 by $0.78. The biopharmaceutical company earned $3.36 billion during the quarter, compared to analyst estimates of $3.23 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 18.61% and a net margin of 30.47%. The firm's revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $9.98 EPS. Read the conference call transcript. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), American CenturyFocused Dynamic Growth ETF (FDG) and Subversive Mental Health ETF (SANE). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More This page (NASDAQ:REGN) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.